Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymph Node Excision | 1 | 2017 | 20 | 0.560 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2017 | 15 | 0.550 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2017 | 15 | 0.550 |
Why?
|
| Lymph Nodes | 1 | 2017 | 61 | 0.550 |
Why?
|
| National Health Programs | 1 | 2002 | 3 | 0.200 |
Why?
|
| State Medicine | 1 | 2002 | 3 | 0.200 |
Why?
|
| Family Practice | 1 | 2002 | 14 | 0.200 |
Why?
|
| Esophageal pH Monitoring | 1 | 2020 | 2 | 0.170 |
Why?
|
| Survival Rate | 2 | 2018 | 270 | 0.160 |
Why?
|
| beta-Thalassemia | 2 | 2010 | 2 | 0.160 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 26 | 0.160 |
Why?
|
| Hydroxyurea | 2 | 2010 | 29 | 0.160 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 108 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 67 | 0.150 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2017 | 1 | 0.140 |
Why?
|
| Antigens, Surface | 1 | 2017 | 11 | 0.140 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 36 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 31 | 0.140 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 44 | 0.140 |
Why?
|
| Fundoplication | 1 | 2017 | 19 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 53 | 0.140 |
Why?
|
| Operative Time | 1 | 2017 | 81 | 0.130 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 26 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 295 | 0.130 |
Why?
|
| Middle Aged | 6 | 2020 | 7555 | 0.130 |
Why?
|
| Aged | 6 | 2020 | 7669 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 66 | 0.130 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 307 | 0.130 |
Why?
|
| Laparoscopy | 1 | 2017 | 137 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2017 | 184 | 0.120 |
Why?
|
| Male | 8 | 2020 | 12453 | 0.120 |
Why?
|
| Female | 8 | 2020 | 12677 | 0.120 |
Why?
|
| Adult | 6 | 2017 | 6584 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2017 | 189 | 0.110 |
Why?
|
| Humans | 11 | 2020 | 22848 | 0.110 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2013 | 1 | 0.100 |
Why?
|
| Trigonella | 1 | 2013 | 1 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2013 | 11 | 0.100 |
Why?
|
| Levodopa | 1 | 2013 | 30 | 0.100 |
Why?
|
| Noise, Occupational | 1 | 2012 | 2 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 1494 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 25 | 0.100 |
Why?
|
| Operating Rooms | 1 | 2012 | 13 | 0.100 |
Why?
|
| Hemoglobin E | 1 | 2010 | 1 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2010 | 61 | 0.080 |
Why?
|
| Parkinson Disease | 1 | 2013 | 556 | 0.070 |
Why?
|
| Young Adult | 3 | 2017 | 1721 | 0.050 |
Why?
|
| Appointments and Schedules | 1 | 2002 | 9 | 0.050 |
Why?
|
| Australia | 1 | 2002 | 41 | 0.050 |
Why?
|
| United Kingdom | 1 | 2002 | 42 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2020 | 1528 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2002 | 71 | 0.050 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2000 | 3 | 0.040 |
Why?
|
| Multimedia | 1 | 2020 | 3 | 0.040 |
Why?
|
| Comprehension | 1 | 2020 | 26 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 47 | 0.040 |
Why?
|
| Mutation | 2 | 2010 | 284 | 0.040 |
Why?
|
| Cardia | 1 | 2018 | 3 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 21 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 36 | 0.040 |
Why?
|
| Esophagectomy | 1 | 2018 | 15 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 59 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 42 | 0.040 |
Why?
|
| Gastrectomy | 1 | 2018 | 26 | 0.040 |
Why?
|
| Microvessels | 1 | 2017 | 11 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 77 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 81 | 0.040 |
Why?
|
| New York City | 1 | 2017 | 11 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 32 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 165 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 300 | 0.030 |
Why?
|
| Child | 2 | 2010 | 990 | 0.030 |
Why?
|
| Adolescent | 2 | 2010 | 1775 | 0.030 |
Why?
|
| Seeds | 1 | 2013 | 1 | 0.030 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2013 | 3 | 0.030 |
Why?
|
| Extracorporeal Circulation | 1 | 2012 | 2 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2012 | 9 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2012 | 21 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2012 | 24 | 0.020 |
Why?
|
| United States | 1 | 2018 | 1726 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 295 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2010 | 2960 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2010 | 2 | 0.020 |
Why?
|
| Ferritins | 1 | 2010 | 4 | 0.020 |
Why?
|
| beta-Globins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 2009 | 1 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2009 | 4 | 0.020 |
Why?
|
| India | 1 | 2009 | 12 | 0.020 |
Why?
|
| Hematology | 1 | 2009 | 4 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 214 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 47 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 4055 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 301 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 3062 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2009 | 254 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 215 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 489 | 0.020 |
Why?
|
| Pakistan | 1 | 2000 | 1 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2000 | 96 | 0.010 |
Why?
|